Literature DB >> 27391466

Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.

Daniel J Kagedan1, Liza Abraham2, Nik Goyert3, Qing Li4, Lawrence F Paszat2,3,4, Alexander Kiss3,4,5, Craig C Earle2,3,4, Nicole Mittmann6, Natalie G Coburn7,8,9,10.   

Abstract

BACKGROUND: The single-payer universal health care system in Ontario, Canada creates a setting with reduced socioeconomic barriers to treatment. Herein, the authors sought to elucidate the influence of sociodemographic marginalization on receipt of pancreatectomy, overall survival (OS), and receipt of adjuvant treatment among patients diagnosed with pancreatic cancer at the population level using an observational cohort study design.
METHODS: Patients diagnosed with pancreatic cancer in Ontario between January 2005 and January 2010 were identified using the provincial cancer registry and linked to administrative databases. Census data obtained from each patient's postal code were used as a proxy for that patient's median income, residential instability, material deprivation, ethnic concentration, and dependency (percentage aged <15 years, aged >65 years, and unemployed). Surgical specimen pathology reports were abstracted for histopathology and margin status. Independent predictors of undergoing pancreatectomy, OS after surgical resection, and receipt of adjuvant treatment were identified by logistic regression and Cox proportional hazards analysis.
RESULTS: Of the 6296 patients diagnosed with pancreatic cancer, 820 (13%) underwent resection of their tumor. Increasing levels of residential instability (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.80-0.94) and material deprivation (OR, 0.86; 95% CI, 0.79-0.94) predicted a decreased likelihood of undergoing surgical resection. Patients living in rural areas (OR, 0.68; 95% CI, 0.51-0.91) and those living in urban areas with lower incomes (OR range, 0.49-0.77) were found to have a lower likelihood of undergoing surgical resection compared with patients in the urban areas with the highest income. After surgical resection, an association between sociodemographic marginalization with OS or receipt of adjuvant treatment was not identified.
CONCLUSIONS: Sociodemographic marginalization exerts its influence early in the pancreatic cancer care continuum, and appears to be associated more with which patients undergo surgical resection than the receipt of adjuvant treatment. Cancer 2016;122:3175-82.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  adjuvant chemotherapy; adjuvant radiotherapy; pancreatectomy; pancreatic cancer; population; social marginalization

Mesh:

Year:  2016        PMID: 27391466     DOI: 10.1002/cncr.30148

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Changes in preoperative endoscopic and percutaneous bile drainage in patients with periampullary cancer undergoing pancreaticoduodenectomy in Ontario: effect on clinical practice of a randomized trial.

Authors:  D J Kagedan; J D Mosko; M E Dixon; P J Karanicolas; A C Wei; N Goyert; Q Li; N Mittmann; N G Coburn
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

2.  The Impact of Increasing Hospital Volume on 90-Day Postoperative Outcomes Following Pancreaticoduodenectomy.

Authors:  Daniel J Kagedan; Nik Goyert; Qing Li; Lawrence Paszat; Alexander Kiss; Craig C Earle; Paul J Karanicolas; Alice C Wei; Nicole Mittmann; Natalie G Coburn
Journal:  J Gastrointest Surg       Date:  2017-01-05       Impact factor: 3.452

Review 3.  Systematic review of the predictors of health service use in pancreatic cancer.

Authors:  Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

4.  Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.

Authors:  Julie Hallet; Nicole J Look Hong; Victoria Zuk; Laura E Davis; Vaibhav Gupta; Craig C Earle; Nicole Mittmann; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2019-12-13       Impact factor: 7.370

5.  Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.

Authors:  Julie Hallet; Laura E Davis; Alyson L Mahar; Ying Liu; Victoria Zuk; Vaibhav Gupta; Craig C Earle; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2019-10-18       Impact factor: 7.370

6.  Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.

Authors:  Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

7.  Updated risk factors to inform early pancreatic cancer screening and identify high risk patients.

Authors:  Daniel R Principe; Ajay Rana
Journal:  Cancer Lett       Date:  2020-05-08       Impact factor: 9.756

8.  Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study.

Authors:  Jakob Kirkegård; Morten Ladekarl; Claus Wilki Fristrup; Carsten Palnæs Hansen; Mogens Sall; Frank Viborg Mortensen
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

9.  Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma.

Authors:  N Latchana; L Davis; N G Coburn; A Mahar; Y Liu; A Hammad; D Kagedan; M Elmi; M Siddiqui; C C Earle; J Hallet
Journal:  BJS Open       Date:  2018-12-05

10.  Patterns of First-Line Systemic Therapy Delivery and Outcomes in Advanced Epithelial Ovarian Cancer in Ontario.

Authors:  Shiru L Liu; Wing C Chan; Geneviève Bouchard-Fortier; Stephanie Lheureux; Sarah E Ferguson; Monika K Krzyzanowska
Journal:  Curr Oncol       Date:  2022-08-22       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.